CAR-T Meeting 2025 | Factors clinicians should consider when selecting patients with ALL for CAR-T therapy
Pere Barba
• 7 Feb 2025
In this video, Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, comments on the factors to consider when selecting patients with acute lymphoblastic leukemia (ALL) for CAR-T therapy. Dr Barba highlights that tumor burden is a crucial factor, but notes that patients may experience changes in tumor burden after apheresis due to bridging therapy. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
